This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Abstract (Core Conclusions First) KRAS is the most frequently mutated oncogene in human cancer, present in ~30% of all tumors, with the highest burden in pancreatic ductal adenocarcinoma (PDAC, ~90%), colorectal cancer (CRC, ~40–45%), and non-small cell lung cancer (NSCLC, ~25–30%). The field has exploded from zero approved drugs pre-2021 to six approved agents as of early 2026, all small molecules, with a total pipeline of 741 drug entries across all modalities. Three strategic conclusions: Traditionally, compiling this…
Author: Eureka LS
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary The Alzheimer’s Disease (AD) drug arena has undergone a structural reset since 2023. The FDA approvals of lecanemab (Biogen/Eisai, Jan 2023) and donanemab (Eli Lilly, Jul 2024) validated the amyloid-clearance hypothesis and created the first commercially viable disease-modifying therapy (DMT) category. However, the field is rapidly diversifying: tau-targeting, neuroinflammation (TREM2), GLP-1 receptor agonism, and cholinergic/muscarinic routes are all advancing in parallel. The landscape is moderately concentrated at the top (Biogen/Eisai and Eli Lilly lead the…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary The global asthma drug market is a high-volume, high-value arena with approximately 262 million patients worldwide and 664 active development assets across all stages. The competitive arena is structurally bifurcated: a large, commoditized small-molecule segment (ICS, LABA, LAMA, and their combinations) and a rapidly growing, high-margin biologic segment targeting the Type 2 inflammatory axis (IL-4Rα, IL-5/IL-5Rα, TSLP, IL-33). AstraZeneca and GSK are the undisputed Tier 1 leaders in biologics, each holding multiple approved assets and the…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Core Conclusions: Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated—from extracting molecules to mapping competitive pipelines—into a structured output like the report below. Section I: Disease Profile & Epidemiology Part i: Disease Overview IPF (MeSH: D054990) is a chronic, progressive, fatal interstitial lung disease of unknown etiology, characterized by usual interstitial pneumonia (UIP)…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. CD3 is the most clinically validated T-cell co-receptor target in oncology, with 1,023 drugs linked to it in the database and 12 FDA/EMA-approved bispecific T-cell engagers (TCEs) between 2014 and April 2025 — an unprecedented approval pace for any single target. The competitive arena is highly concentrated: Johnson & Johnson (Janssen), Amgen, Regeneron, and Roche/Genentech collectively hold 8 of the 12 approved drugs. Hematologic malignancies (multiple myeloma, B-cell lymphomas, ALL) have been the primary proving ground, but the…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Core Conclusions: Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated—from extracting molecules to mapping competitive pipelines—into a structured output like the report below. Section I: Target Profile ERBB2 (HER2/ErbB-2) is a receptor tyrosine-protein kinase encoded by the ERBB2 gene (HGNC: 3430; UniProt: P04626; NCBI Gene: 2064). It is a member of the ErbB/HER family of receptor…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Core Conclusions: Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated—from extracting molecules to mapping competitive pipelines—into a structured output like the report below. Section I: Target Biology — FGFR2 Overview FGFR2 (Fibroblast Growth Factor Receptor 2; UniProt P21802; HGNC 3689) is a transmembrane receptor tyrosine kinase that transduces signals from FGF ligands to…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Core Conclusions: Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated—from extracting molecules to mapping competitive pipelines—into a structured output like the report below. Section I: Arena Overview Competitive Arena Map Player Summary Table PlayerRegionTierPrimary RouteKey Approved Lung AssetsAstraZenecaUK/GlobalT1EGFR TKI (1st–3rd gen) + HER3 ADC + KRASOsimertinib, Savolitinib, Datopotamab deruxtecan, ZorifertinibMerck (MSD)US/GlobalT1PD-1 checkpoint +…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Core Conclusions: Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated—from extracting molecules to mapping competitive pipelines—into a structured output like the report below. Section I: Disease Profile & Epidemiology i. Disease Definition Psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by erythematous, dry, scaling plaques driven by accelerated epidermopoiesis. It has strong genetic determinants…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Small molecule drugs remain the backbone of the global pharmaceutical industry, with 66,707 total assets tracked globally, 4,635 approved, and 709 currently in Phase 3. The arena is dominated by a handful of Western mega-pharma incumbents — Pfizer, Merck, Roche, Novartis, and AstraZeneca — who collectively hold the largest pipeline volumes and deepest approved portfolios. Oncology (particularly kinase inhibitors) and metabolic disease (SGLT2i, GLP-1 receptor agonist oral forms, DPP-4i) are the two hottest therapeutic areas, with KRAS inhibitors and CDK4/6 inhibitors representing…